Journal
CLINICAL AND EXPERIMENTAL DERMATOLOGY
Volume 47, Issue 3, Pages 611-613Publisher
WILEY
DOI: 10.1111/ced.15007
Keywords
-
Categories
Ask authors/readers for more resources
This case suggests a possible causal association between the COVID-19 vaccine and linear IgA bullous dermatosis, highlighting the importance of monitoring for immune-mediated bullous diseases following vaccination.
A case of linear IgA bullous dermatosis developing 3 days after the second dose of Oxford AstraZeneca COVID-19 vaccine in an adult patient, suggesting a possible causal association. It is worth keeping in mind that COVID-19 vaccination could induce immune-mediated bullous disease in susceptible people.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available